Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Abbey R SadowskiHeather L GardnerAntonella BorgattiHeather WilsonDavid M VailJoshua LachowiczChristina ManleyAvenelle TurnerMary K KleinAngharad WaiteAlexandra SahoraCheryl A London

Published in: BMC veterinary research (2018)

These data demonstrate that KPT-335 has biologic activity in canine lymphoma, and support continued evaluation of SINE compounds such as KPT-335 in combination with standard chemotherapeutics in canine lymphoma.

Keyphrases

phase ii study
diffuse large b cell lymphoma
open label
radiation therapy
clinical trial
squamous cell carcinoma
randomized controlled trial
big data
deep learning
artificial intelligence